Roche Obesity Drug Linked With Increased Risk of Colon Cancer
Posted on: Wednesday, 12 April 2006, 21:00 CDT
A US consumer group has linked Roche's obesity drug Xenical with a precursor to colon cancer, and has petitioned the FDA to remove the drug from the market.
The consumer group, Public Citizen, said that the obesity treatment can cause a significant increase in aberrant crypt foci (ACF) - widely believed to be a precursor to colon cancer.
Recently, GlaxoSmithKline, which has the rights to sell over-the-counter (OTC)Xenical, received a letter from the FDA indicating that the drug may be approvable for non-prescription sales.
Public Citizen's petition is based on findings from the pharmacology review of Roche's own data and a recent independent confirmation that Xenical causes ACF in the colon of rats.
"The failure to ban the prescription version of this drug or, worse, to make it much more widely available by allowing OTC sales, is a decision that is likely to increase cancer incidence," said Dr Sidney Wolfe, director of Public Citizen's Health Research Group.
Source: Datamonitor
Related Articles
- Heart Drugs Show Promise In The Fight Against Colon Cancer
- 1 In 10 Advanced Colon Cancer Patients Worry About Prescription Drug Costs
- Mixing Two Colon Cancer Drugs Has Adverse Effect
- More Drugs Added to Colon-Cancer Guide
- Agencourt Genomic Services Is Key Collaborator in New Study on Breast and Colon Cancer Genes
- Colon Cancer Drugs Should Not Be Stopped Early
- Dual-drug Therapy Targets One Colon Cancer Gene
- Study: Drug Can Reduce Colon Cancer Risk
- Colon Cancer Drug Shows Some Good Results
 |
 |
User Comments (0)
RSS Feeds